Carnot ICM

The ICM Carnot Institute is comprised of a research center, a center for clinical investigation and an incubator for start-ups dedicated to finding solutions for diseases and disorders of the central nervous system.

Headquartered in a 22,000 sqm building equipped with the latest technological core facilities, our goal is to promote strong partnerships as a means to accelerate translational research and respond to industry actors unmet needs.

Competences

Core business

Health
Technologies for health
Key figures
Fermer

Key figures

Permanent staff (full-time equivalent)
440
including PhD Students
95
Global budget
41,2 M€
Partnership
incomes with industry
11 M€
Contact
Fermer

Contact

institut Carnot ICM
Hôpital Pitié-Salpétrière,
47/83 boulevard de l'hôpital
75013 Paris

Alexis GENIN 
+33 (0)1 57 27 40 69

Email contact
Parent institutions
Fermer

Parent institutions

  • ICM
  • CNRS
  • Inserm
  • APHP
  • UPMC

Presentation

The ICM addresses brain and spinal cord disorders by accelerating the development of new health solutions

Personalised Medicine

The ICM has structured its research strategy into key thematic and transversal axis according to the unmet needs of «translational» research in the field of Neuroscience.

Patient cohorts, biomarkers identification and the validation of new therapeutic targets allow for patients affected by Parkinson’s disease, Alzheimer’s disease, multiple sclerosis or neuro-oncological tumors to benefit from personalized diagnosis and foresight into how they will respond to treatments.

Medtech approaches

Identified biomarkers can be circulating molecules, neuroimaging signals, electroencephalographic traces, responses to cognitive tests or other «markers». Those new markers and their combination are identified at ICM by capitalizing on extensive patients cohorts and through the development of new technologies, used as measurement tools as well as a means to modulate brain activity: deep brain stimulation, therapeutic ultrasounds, transcranial magnetic stimulation, etc. are being developed at the ICM Carnot Institute thanks to 7,000 sqm of technological core facilities.

Target markets

  • Biotechnology
  • Medical technology
  • Digital health

 

Digital tools for active ageing and disease monitoring

With the view of constructing a “hospital of the future”, promoting home-based care for patients and preventing age-related comorbidities, the ICM Carnot Institute is developing, thanks to its joint academia/industry laboratories and the innovative companies of its iPEPS-ICM incubator, ultra-early diagnostic tools for diseases and digital tools for maintaining patients’ autonomy: smartphone applications, connected devices, medical devices, serious games. In order to understand and manage motivation-related disorders, a unique living lab allows for experimentation around potential solutions.

Knowledge and know-how

  • Genetics
  • Transgenesis
  • Preclinical studies
  • Clinical trials
  • Neuroimaging
  • Biostatistics
  • Biomarker research

Examples of core facilities:

  • Virtual reality
  • MEG/EEG
  • MRI
  • Cellular imaging
  • Electrophysiology
  • Preclinical functional exploration
      Deep Brain Stimulation in Parkinson’s disease: treatment consists of electrically stimulating a deep brain structure called the subthalamic nucleus, which causes a dramatic decrease in motor disorders. Electrodes are implanted in a specific region of the brain and are stimulated via a pacemaker, placed under the skin at the patient’s clavicle. (Atlas YeB).